Publications by authors named "L Friboulet"
Article Synopsis
- FGFR inhibitors have shown promise in treating FGFR-altered cholangiocarcinoma, but acquired resistance poses a challenge to their effectiveness.
- The study utilized diverse investigative methods, including DNA analysis and tissue biopsies, to explore resistance mechanisms in a cohort of patients.
- Results indicated that a significant number of patients with clinical benefits had specific FGFR2 mutations, but polyclonal resistance was influenced by low drug concentrations and specific mutation types affecting drug efficacy.
Article Synopsis
- Metastatic urothelial carcinoma (mUC) is a dangerous cancer with few treatment options, and its genetic makeup is not fully understood unlike non-metastatic urothelial carcinoma (UC).
- A study analyzing genetic data from 111 mUC biopsies found that common genetic changes are similar to those seen in primary UC and highlighted mutational signatures related to APOBEC, platinum sensitivity, and homologous recombination deficiency.
- The research revealed that a significant portion of mUC patients have potential therapeutic targets, with the most common being FGFR3, ERBB2, TSC1, and PIK3CA, and noted that certain genes like NECTIN4 and TACSTD2 are consistently highly expressed across different
Article Synopsis
- - The MATCH-R trial aimed to analyze the resistance mechanisms to cancer treatments by studying fresh tumor biopsies from metastatic patients, covering data collected from 2015 to 2022.
- - Out of 1,120 biopsies from patients primarily with lung, digestive, and prostate cancers, 30.9% revealed targetable genomic alterations, with EGFR being the most common altered gene.
- - Among patients with resistance mechanisms, 45% had treatments tailored based on identified mechanisms, resulting in an average of 11 months of additional clinical benefit.
Cancer Discov
December 2024
Article Synopsis
- Three generations of tyrosine kinase inhibitors (TKIs) exist for ALK fusion-positive non-small cell lung cancer, but they fail to effectively address resistance, brain activity, and TRK inhibition issues.*
-
- NVL-655, a new TKI, shows superior selectivity and potency against ALK mutations, significantly outperforming current approved ALK TKIs in preclinical studies.*
-
- Preliminary results from a phase I/II trial indicate NVL-655's promise for treating heavily pretreated patients, including those with brain metastases and resistance mutations, potentially making it a fourth-generation advancement for ALK-driven cancers.*
